Hainan Huluwa Pharmaceutical Group announced that the company recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the oseltamivir phosphate capsules. The drug is a capsule formulation with a specification of 75mg, registered under the classification of chemical drugs Class 4. The company has cumulatively invested RMB 7.5278 million in research and development. This drug is classified as a Category B variety in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List, and has been included in the 2018 China National Essential Medicines List. Its indications include the treatment of influenza types A and B in adults and children aged 1 year and older, as well as the prevention of influenza types A and B in adults and adolescents aged 13 years and older. The approval of this drug will further enrich the company's product line and play a positive role in the company's development.